← Back to Clinical Trials
Recruiting NCT04707729

NCT04707729 ROX Index for the Timing of Intubation in Nasal High Flow

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04707729
Status Recruiting
Phase
Sponsor Hospital Universitari Vall d'Hebron Research Institute
Condition Acute Hypoxemic Respiratory Failure
Study Type INTERVENTIONAL
Enrollment 630 participants
Start Date 2020-12-09
Primary Completion 2024-12-31

Trial Parameters

Condition Acute Hypoxemic Respiratory Failure
Sponsor Hospital Universitari Vall d'Hebron Research Institute
Study Type INTERVENTIONAL
Phase N/A
Enrollment 630
Sex ALL
Min Age 18 Years
Max Age 120 Years
Start Date 2020-12-09
Completion 2024-12-31
Interventions
ROX index algorithm

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Late or delayed intubation in patients with acute hypoxemic respiratory failure (AHRF) treated with nasal high flow (NHF) is associated with increased patient mortality. The ROX index has been designed and validated to predict outcome of NFH therapy by identifying those patients with a high risk of NHF failure and those with a high probability of success. Whether or not the ROX index may improve patient outcome remains to be shown. To do so, a strategy using the ROX index must lead to earlier intubation than commonly-used criteria. The objective of the ROX-1 trial is to assess whether the use of an algorithm incorporating the ROX index to standard of care for the time to intubation in patients with AHRF supported with NHF isassociated with an increase in the proportion of patients who are intubated within the first 12 hours among those patients who fail on NHF.

Eligibility Criteria

Inclusion Criteria: * All consecutive patients older than 18 years with acute hypoxemic respiratory failure who need to be supported with nasal high flow (NHF) will be considered for inclusion. * Criteria for initiation of NHF if they had a respiratory rate \> 25 breaths/min and/or pulse oximetry (SpO2) \< 92% while receiving standard oxygen administered through a facemask at 10 L/mn or more. * Patients already treated with NHF for acute respiratory failure prior to ICU admission will be enrolled if duration of NHF prior to randomization does not exceed one hour. Exclusion Criteria: * Patients younger than 18 years old. * Patients with indication for immediate intubation. * Patients treated with NHF for more than 1h prior to randomization. * Patients with do-not-intubate order. * Patients electively intubated for diagnostic or therapeutic procedures. (fibrobronchoscopy, surgery). * Patients with no pulmonary infiltrates on chest X-ray * Patient with post-extubation AHRF. * Awake ECMO.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology